In the heavyweight title match between weight loss meds, we have ourselves a victor.In the battle between Novo Nordisk’s ...
The study concentrates on the FDA-approved injectable medications semaglutide and liraglutide. A study conducted by the ...
The Clinical Trials Arena team investigates assets in infectious diseases, metabolic disorders, oncology and ophthalmology.
Liraglutide lowered body mass, slowed weight gain and improved health markers in kids ages 6 through 11, according to ...
Evidence shows that blockbuster weight-loss medications can reduce obesity even in children aged 6–11, but their long-term ...
Currently, there are no approved medications for treating nonmonogenic, nonsyndromic obesity in children under 12. While ...
Liraglutide treatment significantly lowers BMI in obese children aged 6 to <12, but gastrointestinal side effects prompt the ...
Liraglutide is the first GLP-1 agonist to show benefit in this age group and could provide young patients a much-needed ...
Recently, GLP-1 receptor agonist medications have been prescribed more commonly, in part due to their ability to produce ...